11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne(University of Turku), Michael Grundman(University of San Diego), Kaj Blennow(Sahlgrenska University Hospital), Chester A. Mathis(University of Pittsburgh), Sofia Rodriguez Martinez de Liano(Imperial College London), Martin N. Rossor(National Hospital for Neurology and Neurosurgery), William E. Klunk(University of Pittsburgh), David J. Brooks(Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Aren Okello(Imperial College London), Jerome Barakos(Sutter Health), Roger Bullock, Ronald S. Black(Pfizer (United States)), Martin Koller(Heidelberg University), Keith M. Gregg(Janssen (United States)), Enchi Liu(University of Washington), Dale Schenk(Athena Group (United States)), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit)
Cited by 696
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k